Paper Details

  1. Home
  2. Paper Details

Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial.

Author: FretzinScott, GottliebAlice, GuzzoCynthia, KavanaughArthur, KunynetzRod, LiShu, MendelsohnAlan, MenterAlan, ShenYaung-Kaung

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Some people with psoriatic arthritis don't respond to standard treatments, so new options are needed. Research suggests that interleukins 12 and 23 might be involved in the symptoms and joint damage of psoriatic arthritis. Ustekinumab is a medication that blocks these substances. This phase II study examines the effectiveness and safety of ustekinumab for psoriatic arthritis.
Paper Details　
Original Abstract of the Article :
Since some patients with psoriatic arthritis do not respond to typical drug treatments, alternatives are needed. Findings suggest that interleukins 12 and 23 might affect clinical symptoms and pathological joint changes of psoriatic arthritis. Ustekinumab is a human monoclonal antibody that inhibits...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/S0140-6736(09)60140-9

データ提供：米国国立医学図書館（NLM）

Ustekinumab: A Novel Treatment for Psoriatic Arthritis

Psoriatic arthritis, a chronic inflammatory condition that affects both the skin and joints, can be as debilitating as a sandstorm. This study explores the potential of ustekinumab, a human monoclonal antibody, as a novel treatment for this challenging disease. The authors conducted a phase II study to assess the efficacy and safety of ustekinumab in patients with psoriatic arthritis.

Ustekinumab: A Promising New Frontier

The study revealed that ustekinumab effectively reduced symptoms and improved joint function in patients with psoriatic arthritis. These results suggest that ustekinumab could be a valuable addition to the therapeutic arsenal for this debilitating condition.

Health Implications and Practical Applications

For individuals with psoriatic arthritis, ustekinumab offers a new hope for managing their condition. However, it's essential to consult with a healthcare professional to determine if ustekinumab is the right treatment option. Just as a camel adapts to its environment, we must find the right treatment to manage our individual health challenges.

Dr. Camel's Conclusion

This research offers a glimmer of hope for individuals struggling with psoriatic arthritis. The promising results of this study suggest that ustekinumab could provide a new path for managing this chronic inflammatory condition. As we continue to explore new frontiers in medicine, we can find solace in the knowledge that innovative treatments are continually emerging, offering a beacon of hope for those navigating the complexities of illness.

Date :
  1. Date Completed 2009-03-05
  2. Date Revised 2022-04-09
Further Info :

Pubmed ID

19217154

DOI: Digital Object Identifier

10.1016/S0140-6736(09)60140-9

Related Literature

Article Analysis
・Effective treatment of psoriatic arthritis
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.